- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials Sponsored by Zhejiang Litongde Hospital
Total 2076 results
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Zhejiang Cancer HospitalRecruitingColorectal Cancer Metastatic | Microsatellite Stable | Mismatch Repair-proficientChina
-
Zhejiang Cancer HospitalRecruiting
-
Zhejiang Cancer HospitalRecruiting
-
Zhejiang Cancer HospitalRecruitingCervical CancerChina
-
Zhejiang Cancer HospitalNot yet recruitingSmall Cell Lung Cancer Extensive Stage
-
Zhejiang Cancer HospitalNot yet recruitingGastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and SurgeryChina
-
Zhejiang Cancer HospitalNot yet recruitingChemotherapy Effect | Gray Zone Lymphoma | Relapse/Recurrence
-
Zhejiang Cancer HospitalNot yet recruiting
-
Zhejiang Cancer HospitalNot yet recruitingLocally Advanced Rectal CancerChina
-
Zhejiang Cancer HospitalNot yet recruiting
-
Zhejiang Cancer HospitalNot yet recruitingUnresectable Stage III NSCLC
-
Zhejiang Cancer HospitalRecruitingGastric AdenocarcinomaChina
-
Zhejiang Cancer HospitalRecruitingSurgery | Esophageal Carcinoma | Neoadjuvant ChemoradiotherapyChina
-
Zhejiang Cancer HospitalRecruitingNeoplasm Metastasis | Nasopharyngeal CancerChina
-
Zhejiang Cancer HospitalCompletedNasopharyngeal CarcinomaChina
-
Zhejiang Cancer HospitalActive, not recruitingNon-small Cell Lung Cancer | PDL1 Gene MutationChina
-
Zhejiang Cancer HospitalCompletedPathological Conditions, Signs and SymptomsChina
-
Zhejiang Cancer HospitalCompleted
-
Zhejiang Cancer HospitalActive, not recruitingGastric Cancer | Diagnosis | Multi-omicsChina
-
Zhejiang Cancer HospitalActive, not recruiting
-
Zhejiang Cancer HospitalCompleted
-
Zhejiang Cancer HospitalActive, not recruitingGastric Cancer | Signet Ring Cell CarcinomaChina
-
Zhejiang Cancer HospitalCompletedEndobronchial Metastases | Bronchoesophageal Fistula | General Anesthetic Drug Adverse ReactionChina
-
Zhejiang Cancer HospitalCompletedBreast Cancer | HER2 | Preoperative Systemic Treatment
-
Zhejiang Cancer HospitalUnknownCarcinoma, Hepatocellular
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalUnknownCervical CancerChina
-
Zhejiang Cancer HospitalUnknownPeripheral T Cell LymphomaChina
-
Zhejiang Cancer HospitalUnknownBreast Cancer | Breast Diseases | Neoplasm, BreastChina
-
Zhejiang Cancer HospitalUnknownRectal Neoplasms | Neoadjuvant Therapy | Circulating Tumor DNAChina
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalUnknownBreast Cancer | Breast Neoplasms | Breast Diseases
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalCompletedSafety Issues | Effect of DrugsChina
-
Zhejiang Cancer HospitalUnknownNasopharyngeal CarcinomaChina
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalUnknownNasopharyngeal CarcinomaChina
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalUnknownDrug Safety | Surgically-Created Resection CavityChina
-
Zhejiang Cancer HospitalCompleted
-
Zhejiang Cancer HospitalCompletedEsophageal CancerChina
-
Zhejiang Cancer HospitalCompletedUltrasonography | Lipemia | Endometrium | Mammography | EstrogenChina
-
Zhejiang Cancer HospitalUnknownNon-small Cell Lung CancerChina
-
Zhujiang HospitalNot yet recruitingRecurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor CellChina
-
Zhujiang HospitalNot yet recruitingEfficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year | Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year | All-cause Mortality Events (Within 1 Year) | Incident Ischemic Stroke Events (Within 1 Year) | New Hemorrhagic Stroke Events (Within 1 Year) | New... and other conditions
-
Zhujiang HospitalRecruiting
-
Zhujiang HospitalRecruitingHigh Grade Glioma | Radiation Toxicity | Overall Survival | Progression-free Survival | MRI Simulated PositioningChina